Viking Therapeutics Inc (USD)
VKTX
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range4.31 | 4.58
52-Wk Range |
Last Close4.40
Mkt Cap (m)319.28
Dividend yield-
ISINUS92686J1060
Volume917,493
Exchange VenueNAS

Company Profile

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.

Key Information
Price/Earning-
Price/Book1.15
Price/Sales-
P/CF-
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-8.97
Debt/Equity0.00

Documents

Prospectus
en 02/08/2019
Annual Report
en 31/12/2019

Financials

Income Statement
USD201420152016201720182019
Revenue (m)
Operating Income (m)-23-12-14-19-26-33
Net Income (m)-22-23-15-21-22-26
Basic EPS-7.03-3.68-0.90-0.79-0.38-0.36
Avg. Diluted Shares Outstanding (m)4616265872
Balance Sheet
USD201420152016201720182019
Current Assets (m)1151422302284
Non Current Assets (m)211
Total Assets (m)3151522302284
Current Liabilities (m)2326957
Total Liabilities (m)------
Total Equity (m)-229813298277
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-2-9-11-15-19-25
Capital Expenditure (m)------
Figures are quoted in USD unless stated otherwise
-
No change
$
4.40
Last Price